CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Evolent Health Q3 revenue and profit beat on client expansion, oncology growth

By Reuters News


Overview

  • US healthcare solutions provider's Q3 revenue rose sharply, slightly beating analyst expectations

  • Adjusted EPS for Q3 beat analyst expectations

  • Company reiterated full-year revenue guidance and raised adjusted EBITDA outlook


Outlook

  • Evolent reiterates 2026 revenue guidance of $2.6 bln to $2.7 bln

  • Company raises 2026 Adjusted EBITDA guidance to $130 mln to $135 mln

  • Evolent expects to deploy $26 mln to $28 mln in capital expenditures in 2026


Result Drivers

  • CLIENT EXPANSION - Co cited renewals and expanded agreements with existing health plan customers as key drivers of Q3 growth

  • ONCOLOGY SOLUTIONS - Execution in 2026 oncology launches contributed to results

  • NEW CONTRACTS - Co announced one renewal and two new revenue agreements in Q3, including expanded oncology services and surgical management contract renewal


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Slight Beat*

$725.37 mln

$724.19 mln (15 Analysts)

Q3 Adjusted EPS

Beat

$0.06

$0.05 (12 Analysts)

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Evolent Health, Inc. is $6.00, about 25% above its November 4 closing price of $4.80

  • The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 11 three months ago


Reuters Recommended Reads

  • Nov 4 - Health insurers, hospitals rally after sweeping midterm win for Democrats

  • Nov 4 - CVS beats Q3 revenue, profit estimates, outlook raised; to split into two

  • Nov 4 - Acadia Healthcare Q3 revenue beats estimates; 2026 outlook raised


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.